Cargando…
Contributions of Interleukin-1 Receptor Signaling in Traumatic Brain Injury
Traumatic brain injury (TBI) in various forms affects millions in the United States annually. There are currently no FDA-approved therapies for acute injury or the chronic comorbidities associated with TBI. Acute phases of TBI are characterized by profound neuroinflammation, a process that stimulate...
Autores principales: | Thome, Jason G., Reeder, Evan L., Collins, Sean M., Gopalan, Poornima, Robson, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6985078/ https://www.ncbi.nlm.nih.gov/pubmed/32038189 http://dx.doi.org/10.3389/fnbeh.2019.00287 |
Ejemplares similares
-
Altered Serotonin 2A (5-HT(2A)) Receptor Signaling Underlies Mild TBI-Elicited Deficits in Social Dominance
por: Collins, Sean M., et al.
Publicado: (2022) -
LRRK2 Contributes to Secondary Brain Injury Through a p38/Drosha Signaling Pathway After Traumatic Brain Injury in Rats
por: Rui, Qin, et al.
Publicado: (2018) -
Repetitive Traumatic Brain Injury and Development of Chronic Traumatic Encephalopathy: A Potential Role for Biomarkers in Diagnosis, Prognosis, and Treatment?
por: Turner, Ryan C., et al.
Publicado: (2013) -
Contributions of the immune system to the pathophysiology of traumatic brain injury – evidence by intravital microscopy
por: Schwarzmaier, Susanne M., et al.
Publicado: (2014) -
Interleukin-1 Receptor Antagonist as Therapy for Traumatic Brain Injury
por: Lindblad, Caroline, et al.
Publicado: (2023)